UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

 

December 31, 2012

--------------------------------------------

Date of Report (Date of earliest event reported) 

 

ELITE PHARMACEUTICALS INC.

--------------------------------------------------------

(Exact name of registrant as specified in its charter)

 

 

Nevada

001-15697

 

22-3542636

 

(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)

 

165 Ludlow Avenue, Northvale NJ 07647

------------------------------------------------------------------

(Address of principal executive offices)

 

(201) 750-2646

---------------------------

(Registrant’s telephone number, including area code)

 

 

(Former name or former address, if changed since last report)

 

        Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 
 

 

 

Item 5.02.   Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On December 31, 2012, Ram Potti resigned from the board of directors of Elite Pharmaceuticals, Inc. citing personal reasons. In his resignation, Mr. Potti expressed that he remains committed in his support of Elite as he was while a director of the company.

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

   
 Dated:  January 3, 2012 ELITE PHARMACEUTICALS, INC.
   
   
  By: /s/ Chris Dick
    Chris Dick
    President and Chief Operating Officer